Acinetobacter baumannii — AI-Guided mRNA Vaccine Target Discovery

Carbapenem-resistant Acinetobacter baumannii is a WHO priority pathogen. This manuscript describes a computational framework that analyzes the A. baumannii ATCC 17978 genome (accession CP000521.1) with machine-learning models to predict surface-exposed, immunogenic antigens, and integrates CRISPR-based essentiality data to prioritize targets. Top candidates include outer membrane proteins (OmpA, BamA) and cell-wall or LPS biosynthesis enzymes (MurA, MurB, LpxC). The manuscript is labelled a research proposal / methods paper and states that all in silico predictions require experimental validation.

1. 1

   Genome acquisition — complete ATCC 17978 genome (3,976,747 bp, 38.9% GC).

2. 2

   AI target identification — ORF extraction, surface-protein prediction, epitope prediction and immunogenicity scoring with a weighted selection criteria table.

3. 3

   CRISPR functional integration — essentiality data used to separate essential cell-wall targets from non-essential surface targets.

4. 4

   Epitope mapping — B-cell, MHC-I and MHC-II epitope regions predicted for top targets (OmpA, BamA, LpxC).

5. 5

   mRNA construct design — human codon optimization, α-globin 5′ UTR, β-globin 3′ UTR, modified nucleotides and a signal peptide.

6. 6

   Multi-target formulations — three proposed designs (Core: OmpA + BamA; Enhanced: Core + LpxC + MurA; Comprehensive: Enhanced + CarO + PilA).

1. 1

   Surface antigens such as OmpA and BamA are proposed as targets for neutralizing and adhesion-blocking antibodies.

2. 2

   Essential enzymes such as MurA, MurB and LpxC are proposed as targets for bactericidal immunity.

3. 3

   The mRNA-encoded antigens would be translated by host cells and presented to the immune system (proposed, not demonstrated).

4. 4

   Combined targeting is proposed to address both prevention and clearance — a computational hypothesis only.

All steps describe intended, modeled or proposed behavior — no effect above is experimentally proven or clinically demonstrated.

Acinetobacter baumannii — Computational research proposal

These projects are scientific research designs and computational proof-of-concept studies. They are not approved medical products, experimentally validated cures, or guarantees of therapeutic effectiveness.